Key Takeaways
- Standalone strength, subsidiary drag: Consolidated revenue grew 11.4% YoY driven by 35% standalone growth from domestic defense and space, while international subsidiaries contracted on European ER&D softness.
- Order book hit ₹1,769 crores: New EMS customers entering serial production after NPI qualifications drove the build, even as the BTS order book stayed flat QoQ because of heavy deliveries.
- Margins compressed on mix and subsidiaries: Gross margin fell ~100 bps YoY to 49-50%, and consolidated EBITDA is weighed down by a ₹12 cr subsidiary loss, split roughly evenly between Canada and France.
- A hard call on Canada is imminent: Management expects a decision on the loss-making Canadian subsidiary by end of the current quarter, with the primary objective being to stop the bleeding.
- What to watch next quarter: Whether the Canadian subsidiary decision materializes and stops the ~€2 mn annual loss, whether the Virupaksha Radar development order converts to a visible production pipeline, and whether ER&D demand softness in Europe begins to reverse.
Standalone Business: The Growth Engine
- BTS drove the quarter: Standalone revenue grew 35% YoY, powered by high-margin build-to-spec business for domestic defense and space customers; the segment carries higher gross margins than EMS.
- Order book conversion in motion: The BTS order book was flat QoQ not because bookings slowed but because significant deliveries occurred during the quarter; order booking remains healthy.
- Radar programs anchor the pipeline: A naval radar TR module program with DRDO is in production execution, and a new development order for the Virupaksha Radar (Su-30 platform, ~₹10 cr) was received this quarter with an 18-24 month design and delivery timeline.
- Space positioning is unique: The SBS-3 program has sanctioned budgets with orders spread over at least two years; the company holds proprietary IPO technology on some opportunities and competes on others.
- Land systems and EW add breadth: Investments in equivalent solutions to imported land systems have yielded orders including in the current quarter, while large EW opportunities are in competitive bid stages.
- Standalone margin already at target: Standalone business is already at ~14% EBITDA and expected to maintain or slightly improve that range; the consolidated margin gap comes entirely from subsidiaries.
Nikhil Mallavarapu: "the size of opportunity there can be to the tune of maybe Rs. 1,000 crores or so."
International Subsidiaries: The Problem and the Fix
- ER&D softness hit the top line: International subsidiaries saw degrowth due to demand softness in the ER&D business, driven by delayed customer decisions on new projects amid uncertain macro factors in Europe.
- The softness is concentrated: Demand weakness over the past 18 months has been led by the automotive sector and partially aerospace; the pipeline is now improving, driven by defense customers and some aerospace programs.
- Canada is the acute problem: The Canadian subsidiary was originally carved out from Alstom and acquired as part of a French business acquisition; a declining contract meant to convert to BTS product supply has not delivered margins sufficient to justify costs.
- The loss run-rate is structural: The Canadian entity lost about €2.4 mn last year and roughly €2 mn in each of the two prior years; revenue is very small but the loss is high, primarily employee cost.
- A decision is close: Management is exploring different options under NDA, with the first objective being to stop the loss; a decision is expected by end of the current quarter, with a short period following to close.
- France is the other half: Of the ₹12 cr subsidiary loss, roughly 50% sits in France; the fix is a sales-led recovery focused on key defense and aerospace customers where the pipeline has improved.
- India rail team is a hedge: A 30-40 engineer team in India is already designing equivalent rail solutions, delivering for Delhi and Chennai metros, and won a first order for the Vande Bharat program this quarter.
- UK is a pass-through, not an operating entity: The UK subsidiary exists only as a special-purpose vehicle; investment flows from the parent to Centum UK, which invests in the French company.
K. S. Desikan: "we have lost about € 2.4 million. And in the two years prior to that, also we have been losing about € 2 million each year. And that is the reason that we are trying to take that hard decision of stopping the bleeding by one way or another."
EMS: Diversification and Serial Production
- New customers entering production: The order book grew to ₹1,769 crores driven by new EMS customers transitioning from successful NPI qualifications into the serial production phase.
- NPI qualifications are a leading indicator: New product introduction qualifications involve building prototypes and rigorous testing before mass production; the total value of qualifications completed is roughly USD 15 mn.
- The portfolio is broad and sticky: EMS is diversified across defense, aerospace exports, industrial, energy, medical, and automotive/mobility, with newer customers in semiconductor equipment and biometrics/security; products have 10+ year life cycles.
- Geography adds resilience: The EMS customer base is spread across Europe, the US, and Asia including Israel, Malaysia, and Singapore.
Margins: Mix, Lumps, and the Subsidiary Roadmap
- Gross margin compressed on mix: Gross margin declined ~100 bps YoY from 50-51% to 49-50%, driven by the revenue mix across businesses with different gross margin levels; BTS carries higher gross margins than EMS, while ER&D has no material cost.
- Quarterly EBITDA is inherently lumpy: Margins fluctuate due to mix changes between BTS and EMS segments and varying levels of sales; both contribution percentage and absolute sales level affect the quarterly number.
- The real margin opportunity is subsidiary recovery: Consolidated EBITDA margin target is 13-15%; standalone is already at ~14%, so the improvement must come from subsidiaries currently at roughly 1.5% EBITDA.
- The subsidiary roadmap targets 10-11%: Management is working on a plan to improve subsidiary margin from ~1% to the 10-11% level in roughly two years, through the Canada fix and France sales recovery.
- Revenue recognition is shifting slightly: Historically margin expansion happened in Q4; this year Q1 margin was better compared to last year Q1, though the distribution is still not equal across quarters.
Nikhil Mallavarapu: "The opportunity for improvement will come largely from the subsidiary, which today is at almost, if you look at the last year, was at roughly 1.5% kind of EBITDA level, which is dragging down the overall consolidated number."
The Opportunity Pipeline: Large, Lumpy, and Gated by Government
- Virupaksha Radar opens a large production door: The development order for the Su-30 platform is small (~₹10 cr), but subsequent production orders could be ~₹1,000 cr over 3-4 years; the technologies built can also create opportunities in UAVs, helicopters, and next-gen fighters.
- Tri-services orders are in the pipeline, not the near term: Proposals have been submitted and are in various approval stages within government; pipeline visibility is improving but timing depends on government processes and large orders are not expected in the very short term.
- Space is a nearer-term driver: SBS-3 program budgets are sanctioned with orders spread over multiple years; the company has unique positioning due to proprietary IPO technology on some opportunities and competitive bids on others.
- Start-ups are managed for zero downside: The company works with start-ups on core satellite parts and partnership agreements as prime contractor, but ensures no money is lost by getting paid on the material front at minimum.
- Indra Sistemas MOU remains stalled: No further update; the program is still stalled with no update from the government.
K. S. Desikan: "for the large opportunities, the potential is still there and the pipeline visibility is improving, yet the actual order when we will get depends on the government processes, which seem to be improving, but still we are not able to clearly say, it will happen this year or so."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Canadian subsidiary decision | Decision on stopping losses, with short period following to close | By end of current quarter |
| Consolidated revenue growth | 18% to 20% medium-term growth rate | Medium-term (no fixed year) |
| Standalone revenue growth | 25% plus growth rate (BTS + EMS combined) | Medium-term |
| Consolidated EBITDA margin | 13% to 15% range | Medium-term |
| Subsidiary margin improvement | From ~1% to 10-11% EBITDA level | Roughly two years |
| CAPEX | ₹40 crores in Indian business only; no subsidiary CAPEX | FY26 |
| Asset turns | Move from 6x-7x to 8x-9x | Next year or two |
| H2 performance | Better performance contingent on opportunity conversion | Second half of FY26 |
| Canada and France loss stop | Strategic steps to stop losses in Canada; sales focus to improve France | Coming quarter or two |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Consolidated revenue growth | 11.4% YoY |
| Standalone revenue | ₹180 cr, up 35% YoY |
| Standalone EBITDA | ₹27 cr, up more than 100% YoY |
| Standalone EBITDA margin | 14.92% |
| Consolidated EBITDA margin | ~8.5%, with objective of 13% to 15% |
| Order book | ₹1,769 cr as of 30th June 2025 |
| Order book split | EMS ₹710 cr, BTS ₹886 cr, ER&D services ₹171 cr |
| Standalone BTS revenue | ₹57 cr |
| BTS segment revenue share | improved 600 bps QoQ |
| BTS order execution timeline | 2 to 2.5 years |
| Canadian subsidiary Q1 FY26 loss | €600,000 to €700,000 at EBT level |
| Canadian subsidiary Q1 FY26 revenue | ₹17 to ₹18 cr |
| Subsidiary total loss in Q1 FY26 | ₹12 cr, split roughly 50% Canada, 50% France |
| Medium-term consolidated revenue growth objective | 18% to 20% |
| FY26 CAPEX (standalone, Indian business) | ₹40 cr |
| Standalone asset turns | 6x to 7x currently, expected to reach 8x to 9x in next year or two |
| DRDO development order size | ~₹10 cr |
| NPI qualification value | ~USD 15 million |